Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Tremelimumab vs Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma
2016-004750-15Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- May 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in soft tissue sarcoma (STS) comparing Durvalumab + Tremelimumab with Doxorubicin (2 arms). Primary endpoint: overall survival. Started May 2017; status: completed.
02
Drugs
durvalumabtremelimumabdoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2016-004750-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004750-15.